Higher TRPML1 expression is associated with poorer patient prognosis in head and neck squamous cell carcinoma and bladder urothelial carcinoma characterized by frequent HRAS mutation [21,30]. This evidence concerns the gene MCOLN1 and bladder transitional cell carcinoma.